| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | G2/mitotic-specific cyclin-B1;CCNB1;CCNB; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human TNF beta |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-LTA antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 17L36; isotype IgG; reactivity: Human. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-TNF beta Rabbit Monoclonal Antibody catalog # M00746-2. Tested in WB application. This antibody reacts with Human.
Key elements and design rationale
- Target: LTA (G2/mitotic-specific cyclin-B1).
- Antibody format: Monoclonal; clone 17L36; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
LTA (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Essential for the control of the cell cycle at the G2/M (mitosis) transition. . Reported cellular localization context: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Tissue expression notes (as provided): Ubiquitous. Expressed at high levels in testis.
Research relevance and current trends
- Research context keywords from the source record include: Apoptosis,Apoptotic Markers,Atherosclerosis,Cancer,Cardiovascular,Cell Biology,Cell Death,Invasion/Microenvironment.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate LTA antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect LTA expression by Western blot in cell or tissue lysates, Compare relative LTA levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 133 kDa; calculated MW: 48337 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 133 kDa
- Cellular localization (provided): Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
- Tissue details (provided): Ubiquitous. Expressed at high levels in testis.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
